Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Effective Dose of Statin Post-PCI
Author(s): Morteza Chehrevar , Reza Golchin Vafa , Mohammadhossein Rahmani , et al Added: 1 year ago

Standards & Guidelines

Intervention
ESC 23: The STOPDAPT-3 Study
Author(s): Masahiro Natsuaki Added: 7 months ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111). In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at… View more

MI/ACS

Intervention
View from the Thoraxcenter: ESC 22 Late-breaking Science Preview
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
In this short and engaging episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most impactful hot-line and late-breaking trials from ESC 2022. Which trials should we look out for? Trials covered in detail include: TAILOR-PCI: Tailored Antiplatelet Therapy Following PCI ASCEND: A Study of… View more

Anticoagulation

Imaging & Diagnostics
Stephen D. Wiviott
Job title: Associate Professor
Dr Stephen D Wiviott is senior investigator and chairman of the Clinical Events Committee with the Thrombolysis in Myocardial Infarction (TIMI) Study Group. In addition, he is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and an associate professor of medicine at Harvard Medical School (HMS). Dr Wiviott’s research focuses on platelet function and antiplatelet… View more
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial
Author(s): Harriette Van Spall , Steven E Nissen Added: 1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) to have a deep dive into the practice-changing CLEAR-Outcomes trial (NCT02993406).The Phase 3 CLEAR-Outcomes trial was conducted to evaluate the impact of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular… View more

Standards & Guidelines

Prevention & Chronic Conditions
TCT Connect 2020 Discussion: The VOYAGER PAD Study
Author(s): Mirvat Alasnag , Added: 3 years ago
Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, KSA) and Dr Connie N Hess (University of Colorado School of Medicine, Aurora, CO, US) discuss the results of the sub-analysis of the VOYAGER PAD Study. The VOYAGER PAD trial showed that rivaroxaban/aspirin was superior to aspirin at preventing major adverse limb and cardiovascular events. Dr Hess describes the design of the secondary… View more

Anticoagulation
Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
Author(s): Giulia Magnani , Marco Valgimigli Added: 3 years ago
Dual antiplatelet therapy (DAPT), defined as the use of a P2Y12 receptor inhibitor (clopidogrel, ticagrelor or prasugrel) and aspirin, is required after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).1 Although the use of DES has been shown to reduce the rate of restenosis as compared with bare-metal stents (BMS), there is concern that DES may be associated with a higher… View more

Anticoagulation

Prevention & Chronic Conditions
View from the Thoraxcenter: ESC 22 Late-breaking Science Wrap-up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
What are the take-home messages from ESC 22 and what are the implications for practice? In this short wrap-up video of ESC 22, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) review the most impactful hot line and late-breaking trials of ESC Congress 2022. Trials covered in detail include: On clinical judgement after PCI 00:35:27:REVIVED-BCIS2: Study of… View more

Anticoagulation

Standards & Guidelines